secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001193125-26-001472
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NMRA-511 Phase 1b shows clinically meaningful effect in AD agitation; navacaprant readout in Q2 2026
--------------------------------------------------------------------------------

- NMRA-511 Phase 1b: 15.7-point mean CMAI reduction, no somnolence/sedation; plan higher doses and Phase 2/3 in 2026
- Navacaprant KOASTAL-2 and -3 joint readout in Q2 2026; enrollment increased up to 25% beyond original target of 332
- NMRA-215 Phase 1 for obesity to initiate H1 2026; weight loss data expected around end of 2026
- Cash, cash equivalents and marketable securities support operations into Q3 2027; M4 PAM franchise update mid-2026

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526001472/0001193125-26-001472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526001472/d33765d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-001472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer